Table 3.
Extent of change in HbA1c and body weight with respect to baseline at 6 and 12 months after starting semaglutide treatment.
| No/low CKD risk (n = 296) |
CKD (n = 190) |
P value* | Moderate risk (n = 82) |
High risk (n = 53) |
P value† | Very high risk (n = 45) |
P value‡ | |
|---|---|---|---|---|---|---|---|---|
| HbA1c, Δ vs. bl (%) | ||||||||
| At 6 months | -1.10 (-2.25, -0.40) | -1.20 (-2.45, -0.50) | 0.909 | -1.25 (-2.67, -0.50) | -0.80 (-2.00, -0.20) | 0.114 | -1.25 (-2.30, -0.50) | 0.676 |
| At 12 months | -0.90 (-2.10, -0.40) | -1.20 (-2.50, -0.60) | 0.133 | -1.30 (-2.55, -0.70) | -1.20 (-2.35, -0.05) | 0.209 | -1.35 (-2.90, -0.60) | 0.920 |
| Body weight, Δ vs. bl (kg) | ||||||||
| At 6 months | -5.90 (-9.00, -2.80) | -4.50 (-7.70, -1.60) | 0.008 | -4.80 (-7.95, -1.67) | -4.50 (-8.90, -2.00) | 0.975 | -4.15 (-6.30, -1.00) | 0.169 |
| At 12 months | -6.90 (-11.15, -2.35) | -5.00 (-9.30, -2.30) | 0.087 | -6.00 (-10.25, -2.70) | -5.00 (-9.30, -2.25) | 0.411 | -3.70 (-9.00, -1.85) | 0.336 |
A total of 10 patients who were classified in the group of high/very high CKD risk because their baseline eGFR values were <45 mL/min/1.73 m2 did not have their baseline UACR assessed, and so they could not be further stratified as being of high or very high CKD risk. *CKD vs. no/low CKD risk. †High risk CKD vs. moderate risk CKD. ‡Very high risk CKD vs. moderate risk CKD. Results are expressed as median (IQR). The two-tailed Mann–Whitney U test was used to perform the comparisons.
bl, baseline; CKD, chronic kidney disease; HbA1c, glycosylated hemoglobin; IQR, interquartile range; UACR, urine albumin to creatinine ratio.